CE Mark for PrecisionOne a device that provides automated glucose control and real-time blood chemistry analyses for critical care patients. Admetsys.

Admetsys has received CE mark certification for its PrecisionOne system, a device that provides automated glucose control and real-time blood chemistry analyses for critical care patients. The automated system enables hospitals to provide “safer, more effective care that can scale to meet peak demand, with less manual intervention by clinicians,” the company said. “This is a key element of COVID-19 response and a fundamental factor in hospital preparedness for future public health needs.” The PrecisionOne system is the first fully automated glycemic system and continuous diagnostic platform for hospital care. With the Admetsys system, a tiny laboratory-on-a-chip gets embedded within each patient’s IV line. Every five minutes, that tiny device measures glucose levels, sending the data to a bedside monitor. From there, an algorithm determines how much glucose or insulin a patient needs to maintain glycemic control, and the patient’s medication levels are adjusted automatically. In this closed-loop glucose control system, a nurse never once has to visit the bedside to adjust medication. Moreover, Admetsys designed a user-interface that allows nurses to call up each patient’s profile locally or remotely on any screen.